First-in-Human Trial of the Novel Tuberculosis Vaccine Candidate, H107e/CAF ®10b

Conditions: Healthy Interventions: Biological: H107e; Biological: CAF ®10b; Biological: H107e/CAF®10b - low adjuvant dose; Biological: H107e/CAF®10b - full adjuvant dose; Biological: Low dose intranasal H107e; Biological: Full dose intranasal H107e; Biological: H107e/CAF®10b; Biological: i.m. placebo; Biological: BCG; Biological: i.d. placebo; Biological: Intranas al H107e Sponsors: Statens Serum Institut; Aurum Institute; Bill and Melinda Gates Foundation; Leiden University Medical Center; South African Tuberculosis Vaccine Initiative Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials